粒细胞集落刺激因子在乳腺癌化疗中预防性应用分析  

Preventive application of granulocyte colony stimulating factor in breast cancer chemotherapy

作　　者：陈燕妮[1] 黄新艳[1] 许银燕[1] 谢娟[1] 傅菁[1] CHEN Yan-ni, HUANG Xin-yan, XU Yin-yan, XIE Juan, FU Jing(Obstetrics and Gynecology Hospital Affiliated to Naniing Medical University,Jiangsu Nanjing 210004,Chin)

机构地区：[1]南京医科大学附属妇产医院,江苏南京210004

出　　处：《中国医院药学杂志》2018年第8期854-858,共5页Chinese Journal of Hospital Pharmacy

摘　　要：目的:评价我院粒细胞集落刺激因子(G-CSF)使用的规范性。方法:收集我院2016年7—12月乳腺癌住院患者粒细胞集落刺激因子用药相关信息,并进行统计分析。结果:共收集141例乳腺癌患者556次化疗情况,G-CSF总预防使用率99.64%。G-CSF有250次(46.29%)预防性使用不合理,其中2次(0.37%)使用不足,92次(17.04%)使用过度,156次(28.89%)使用不规范。结论:目前我院乳腺癌化疗不规范应用G-CSF的比例较高,临床医生应提高G-CSF合理应用的意识,临床药师应积极参与到临床用药过程中,促进G-CSF合理应用。OBJECTIVE To evaluate the use of granulocyte colony stimulating factor（G-CSF）in our hospital.METHODSAll patients with breast cancer received chemotherapy from July 2016 to December 2016 were collated,and the use of G-CSF was investigated by statistical analysis.RESULTS There were 141 breast cancer patients received 556 cycles of chemotherapy.Total preventive use rate of G-CSF was 99.64%,250 cycles（46.3%）were irrational,including insufficient use in 2（0.37%）,overuse in 92 cycles（17.04%）and standard use in 156 cycles（28.89%）.CONCLUSION There is a certain proportion of irrational use of G-CSF in our hospital currently.Clinicians should improve the awareness of rational application of G-CSF,and clinical pharmacists should take an active part in the clinical treatment process to promote the rational application of G-CSF.

关 键 词：粒细胞集落刺激因子 乳腺癌 化疗 中性粒细胞减少 合理应用 

分 类 号：R969[医药卫生—药理学]